Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
Healthcare providers who administer the Moderna COVID-19 Vaccine (2023-2024 Formula) to individuals ages 6 months through 11 years should ensure the correct volume of the vaccine (0.25 mL) is withdrawn from the vial and administered to the recipient. Discard vial and excess volume after extracting a single dose.
For additional information, see FDA Announcement and Moderna COVID-19 Vaccine (2023-2024 Formula) Healthcare Provider Fact Sheet (fda.gov)
Summary of recent changes (last updated March 1, 2024):
- All people ages 65 years and older should receive 1 additional dose of any updated (2023–2024 Formula) COVID-19 vaccine (i.e., Moderna, Novavax, Pfizer-BioNTech). For detailed guidance, see Table 1 and Table 2.
- Updated information for reporting adverse events to VAERS following administration of a COVID-19 vaccine.
Reference Materials
- COVID-19 Vaccine Product Information (Updated 11/6/2023)
- FAQs for the Interim Clinical Considerations (Updated 3/4/2024)
- COVID-19 Vaccination Recommendations Infographic (Updated 3/5/2024)
- COVID-19 Vaccination Recommendations Infographic (Immunocompromised) (Updated 10/13/2023)
Get Email Updates
Receive email updates about this page.
Special Situations and Populations